Metropolis Healthcare Ltd (METROPOLIS) is currently trading at 575.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Metropolis Healthcare operates a pathology and diagnostic services network offering routine, semi-specialty, specialty and wellness testing through laboratories, service centres, owned facilities and franchise partners across India and select international markets. Its proposition combines scientific quality, doctor trust, home collection, digital access and increasingly sophisticated genomics and molecular diagnostics capabilities. H1FY27 delivered revenue of INR 947 crore, EBITDA of INR 248 crore and PAT of INR 132 crore, with growth of 16%, 25% and 35% respectively. The notable insight is that mid-teen revenue growth occurred without price increases, while automation, productivity and operating leverage expanded EBITDA margin by 190 basis points. Growth is broad-based across channels and geographies, but the strongest structural signal is the company’s increasing penetration beyond metropolitan markets. Tier III revenue grew approximately 20%, patient volumes increased 10%, and the network now reaches around 750 towns, indicating that access expansion is becoming a meaningful growth engine. Specialty diagnostics and TruHealth are strategic growth engines, each growing 20% in Q2FY27 and contributing 40% and 17% of revenue respectively. New offerings such as a 1000-gene NGS panel, NIPT Advance, pre-eclampsia screening and Alzheimer’s testing are supporting richer mix and reinforcing scientific differentiation. Metropolis 3.0 combines technology-led productivity, scientific expansion, profitable scaling and trust-focused governance. The company is building a digital stack spanning registration, partner management, CRM, customer analytics, AI-enabled reporting and data privacy, while maintaining reported 99.99% accuracy and external quality assurance scores of 99%.

Over the past 52 weeks, Metropolis Healthcare Ltd has traded between a low of ₹413.00 and a high of ₹608.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Metropolis Healthcare Ltd has a market capitalization of approximately 11,856.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Metropolis Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 52.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 11,856.13 Cr, Metropolis Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Metropolis Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Metropolis Healthcare Ltd is 52.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Metropolis Healthcare reported consolidated profit of Rs 75.483 crore for the quarter ended September 30, 2026. That was 43% higher than Rs 52.890 crore in the quarter ended September 30, 2025 and above Rs 56.883 crore in the June 2026 quarter.

Metropolis reported H1 FY27 revenue of Rs 947 crore, up 16% year on year. Management attributed the increase to sustained demand and higher throughput from its expanded Lab & Center network.

Metropolis specialty diagnostics grew 20% year on year in Q2FY27. The segment contributed Rs 198 crore, representing 40% of quarterly revenue. Specialty grew 23% in B2C and 18% in B2B.

Tier III cities contributed 26% of Metropolis domestic revenue in Q2 FY27. Tier I contributed 66% and Tier II contributed 8%, and Metropolis specifies that the city-tier figures cover domestic revenue only.